← Leaderboards
Nurulain T Zaveri
Sri International
$24,519,975
Attributed
$27,326,656
Total exposure
12
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.6M · FY2007–24$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$27,326,656 · 12
By mechanism
U01$9,559,916 · 2
R01$6,754,805 · 2
UH3$4,073,436 · 1
R44$3,001,027 · 2
UG3$2,916,188 · 1
R43$791,664 · 3
Top collaborators
- Kenneth Alan Perkins4 shared
Most similar at Sri International
Same institution · by research overlap
- Thomas S Kilduff$32,452,921
- Lawrence R Toll$15,551,699
Others in their field
Top investigators on “Ligands”
- John Damon Chodera · Sloan-Kettering Inst Can Research$39,009,297
- Keith W Miller · Massachusetts General Hospital$35,506,092
- Ian A Wilson · Scripps Research Institute, The$35,392,112
- Bryan L Roth · Univ Of North Carolina Chapel Hill$32,442,555
- Edward Franklin Plow · Cleveland Clinic Foundation$32,215,714
- Helen M Berman · Rutgers University New Brunswick$32,076,400
Research focus
LigandsAgonistSmall MoleculePharmaceutical PreparationsIn VivoLeadPharmacologySeriesNociceptinDesignPharmacotherapyOpioid ReceptorNovel StrategiesDrug CandidateAffinityPlayRelapseIn VitroBaseRewardsOpioidMorphineSelf AdministrationAttenuated
Grant awards (42)
Development of Next-generation Pharmacotherapy for Opioid Use Disorders$869,673
UH3 · FY2024 · DA · contact PI
First-in-Human Clinical Development of a Novel Drug Candidate with a First-in-Class Mechanism for Smoking Cessation and Abstinence$99,995
U01 · FY2024 · DA · contact PI
Development of Next-generation Pharmacotherapy for Opioid Use Disorders$2,183,507
UH3 · FY2023 · DA · contact PI
First-in-Human Clinical Development of a Novel Drug Candidate with a First-in-Class Mechanism for Smoking Cessation and Abstinence$1,398,808
U01 · FY2023 · DA · contact PI
First-in-Human Clinical Development of a Novel Drug Candidate with a First-in-Class Mechanism for Smoking Cessation and Abstinence$2,107,278
U01 · FY2022 · DA · contact PI
Development of Next-generation Pharmacotherapy for Opioid Use Disorders$1,020,256
UH3 · FY2022 · DA · contact PI
First-in-Human Clinical Development of a Novel Drug Candidate with a First-in-Class Mechanism for Smoking Cessation and Abstinence$2,007,282
U01 · FY2021 · DA · contact PI
Development of Next-generation Pharmacotherapy for Opioid Use Disorders$1,458,094
UG3 · FY2020 · DA · contact PI
DEVELOPMENT OF A NOVEL DRUG CANDIDATE WITH A FIRST-in-CLASS MECHANISM FOR SMOKING CESSATION, RELAPSE and ABSTINENCE$646,565
U01 · FY2020 · DA · contact PI
VALIDATING THE NOCICEPTIN RECEPTOR FOR TREATING CRAVING AND WITHDRAWAL-ASSOCIATED AFFECT IN COCAINE ADDICTION PHARMACOTHERAPY$229,620
U18 · FY2020 · DA · contact PI
DEVELOPMENT OF A NOVEL DRUG CANDIDATE WITH A FIRST-in-CLASS MECHANISM FOR SMOKING CESSATION, RELAPSE and ABSTINENCE$2,158,836
U01 · FY2019 · DA · contact PI
Development of Next-generation Pharmacotherapy for Opioid Use Disorders$1,458,094
UG3 · FY2019 · DA · contact PI
DEVELOPMENT OF A NOVEL DRUG CANDIDATE WITH A FIRST-in-CLASS MECHANISM FOR SMOKING CESSATION, RELAPSE and ABSTINENCE$1,141,152
U01 · FY2018 · DA · contact PI
A NOVEL APPROACH FOR PAIN TREATMENT WITHOUT OPIOID LIABILITIES$736,013
R44 · FY2017 · DA · contact PI
A NOVEL APPROACH FOR PAIN TREATMENT WITHOUT OPIOID LIABILITIES$760,015
R44 · FY2016 · DA · contact PI
PRECLINICAL DEVELOPMENT OF NOVEL SMOKING CESSATION PHARMACOTHERAPIES$5,000
R44 · FY2016 · DA · contact PI
PRECLINICAL DEVELOPMENT OF NOVEL SMOKING CESSATION PHARMACOTHERAPIES$742,129
R44 · FY2015 · DA · contact PI
PRECLINICAL DEVELOPMENT OF NOVEL SMOKING CESSATION PHARMACOTHERAPIES$757,870
R44 · FY2014 · DA · contact PI
Discovery of Bifunctional NOP/Opioid Receptor Ligands for Drug Abuse Therapy$709,446
R01 · FY2014 · DA · contact PI
Discovery of Bifunctional NOP/Opioid Receptor Ligands for Drug Abuse Therapy$11,079
R01 · FY2014 · DA · contact PI
Discovery of Bifunctional NOP/Opioid Receptor Ligands for Drug Abuse Therapy$703,039
R01 · FY2013 · DA · contact PI
Development of Novel Drugs for Smoking Cessation Pharmacotherapy$293,348
R43 · FY2012 · DA · contact PI
Analgesic Potential of NOP Agonists to Treat Pain in Sickle Cell Disease$256,893
R43 · FY2012 · HL · contact PI
Discovery of Bifunctional NOP/Opioid Receptor Ligands for Drug Abuse Therapy$6,794
R01 · FY2012 · DA · contact PI
Discovery of Bifunctional NOP/Opioid Receptor Ligands for Drug Abuse Therapy$1
R01 · FY2012 · DA · contact PI
Discovery of Bifunctional NOP/Opioid Receptor Ligands for Drug Abuse Therapy$646,183
R01 · FY2011 · DA · contact PI
DISCOVERY OF SMALL-MOLECULE ORPHANIN FQ RECEPTOR LIGANDS$191,041
R01 · FY2011 · DA · contact PI
Discovery of Bifunctional NOP/Opioid Receptor Ligands for Drug Abuse Therapy$10,539
R01 · FY2011 · DA · contact PI
Discovery of Bifunctional NOP/Opioid Receptor Ligands for Drug Abuse Therapy$640,287
R01 · FY2010 · DA · contact PI
Development of Novel Therapies for Levodopa-induced Dyskinesia in Parkinson's Dis$241,423
R43 · FY2010 · NS · contact PI
DISCOVERY OF SMALL-MOLECULE ORPHANIN FQ RECEPTOR LIGANDS$196,951
R01 · FY2010 · DA · contact PI
Discovery of Bifunctional NOP/Opioid Receptor Ligands for Drug Abuse Therapy$7,380
R01 · FY2010 · DA · contact PI
Discovery of Bifunctional NOP/Opioid Receptor Ligands for Drug Abuse Therapy$622,553
R01 · FY2009 · DA · contact PI
DISCOVERY OF SMALL-MOLECULE ORPHANIN FQ RECEPTOR LIGANDS$304,447
R01 · FY2009 · DA · contact PI
DISCOVERY OF SMALL-MOLECULE ORPHANIN FQ RECEPTOR LIGANDS$198,940
R01 · FY2009 · DA · contact PI
DISCOVERY OF SMALL-MOLECULE ORPHANIN FQ RECEPTOR LIGANDS$128,345
R01 · FY2009 · DA · contact PI
DISCOVERY OF SMALL-MOLECULE ORPHANIN FQ RECEPTOR LIGANDS$198,940
R01 · FY2008 · DA · contact PI
DISCOVERY OF SMALL-MOLECULE ORPHANIN FQ RECEPTOR LIGANDS$203,300
R01 · FY2007 · DA · contact PI
DISCOVERY OF SMALL-MOLECULE ORPHANIN FQ RECEPTOR LIGANDS$506,924
R01 · FY2004 · DA
DISCOVERY OF SMALL-MOLECULE ORPHANIN FQ RECEPTOR LIGANDS$505,658
R01 · FY2003 · DA
DISCOVERY OF SMALL-MOLECULE ORPHANIN FQ RECEPTOR LIGANDS$506,553
R01 · FY2002 · DA
DESIGN OF SMALL-MOLECULE NOCICEPTIN RECEPTOR LIGANDS$456,405
R01 · FY2001 · DA